GAfPA Blog

The GAfPA Patient Advocacy Blog

VÍDEO: Entender El Cambio O Switch No Médico

Los pacientes con condiciones médicas crónicas o graves a veces deben trabajar con los médicos durante meses para identificar un medicamento que sea eficaz para ellos. Pero como lo explica este video, los pacientes pueden descubrir que este proceso de prueba y error fue en vano. A través del cambio o switch no médico, las … Continued

New Biosimilar Switching Paper Prioritizes Physician-Patient Relationship and Robust Pharmacovigilance

By Brian Kennedy, Executive Director, Global Alliance for Patient Access A new position paper from the European Crohn’s and Colitis Organisation has garnered attention from physicians and patient advocates across Europe. The paper supports switching inflammatory bowel disease patients from an infliximab biologic medicine to a biosimilar – a position that some readers have misinterpreted as an endorsement for switching all patients to … Continued

EU debate on biosimilar drugs

by Brian Kennedy and David Charles Published in the Hippocratic Post, November 15, 2016 Biosimilar medicines have been the hot subject of debate for a number of years. But as health systems around the world face continued budget squeezes and seek to increase the number of patients treated with biosimilars, the use of these less expensive … Continued

VÍDEO: Nombrando medicamentos biosimilares en Latinoamérica

Incluso pequeñas diferencias pueden tener un impacto en cómo un medicamento afecta a su cuerpo. Esto es particularmente cierto con los medicamentos biológicos, que están hechos a partir de células u organismos vivos. Los biológicos a menudo son utilizados en el tratamiento de enfermedades graves como la artritis reumatoide, la psoriasis, la enfermedad de Crohn … Continued

WHO Meeting Looks Forward on Distinguishable Names

By Brian Kennedy, Executive Director, Global Alliance for Patient Access This month’s World Health Organization Open Sessions with INN Stakeholders explored the value, and the future, of the biological qualifier system. The Global Alliance for Patient Access was pleased to present to WHO officials and an international group of fellow stakeholders. While there, I conveyed … Continued

Remsima and Inflectra not inferior to Remicade, NOR-SWITCH study finds

A two year-long Phase IV study has shown Celltrion’s infliximab biosimilar is not inferior to its originator Remicade, but a physician group still urges caution when switching. However, the Global Alliance for Patient Access (GAfPA) – a US non-profit physician group funded by major biopharma and biosimilar makers – expressed its concerns that the results … Continued

Nordic Patient Groups Tackle Biosimilar Policy Issues

Originally published at Institute for Patient Access Biosimilar medicines are being prescribed more and more freely across Europe. But access to, and use of, these new medicines differs greatly depending on which European country you live in.  A recent workshop by the Global Alliance for Patient Access allowed patient advocates from across Europe’s Nordic region … Continued

GAfPA “NOR-SWITCH” Paper Explores Impact of Biosimilar Switching Research

Data from a clinical study in Norway may soon explain the effects of switching stable patients from a biologic medicine, infliximab, to its biosimilar counterpart. But, as the Global Alliance for Patient Access argues in a new white paper, policymakers must accurately interpret what the NOR-SWITCH study will – and will not – demonstrate about the … Continued

GAfPA Asks: What are the Critical International Barriers to Patient Access?

Healthy lives and well-being for all are among the United Nations’ Sustainable Development Goals for 2030. The U.N. calls for “access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all.” But getting necessary medical care to communities across the globe is no simple task. So at … Continued